文献速递神经肿瘤

转移性血管外皮细胞瘤-孤立性纤维肿瘤的监测:关于颅外病变发生率、预测因素与诊断的系统性文献综述

Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease.
PubMed 文献 · J Neurooncol · 2018-03-17

该系统综述检索截至2018年2月1日的Pubmed文献,纳入71项研究,分析颅内血管外皮细胞瘤-孤立性纤维肿瘤(HPC-SFT)颅外转移的发生率、常见部位与出现时间。颅外转移总体发生率为28%(n=251/904),最常见部位为骨(19.6%)、肺与胸膜(18.4%)、肝(17.6%)和椎骨(14.1%)。WHO III级原发肿瘤与颅外转移风险升高相关(1.88,p=0.016)。原文指出缺乏高质量影像监测方案证据,建议多中心研究。

要点

  • 颅内HPC-SFT颅外转移总体发生率为28%(n=251/904),可早至3个月、晚至372个月出现。
  • 颅外转移最常见部位为骨(19.6%)、肺与胸膜(18.4%)、肝(17.6%)、椎骨(14.1%)。
  • WHO III级原发肿瘤与颅外转移风险升高相关(1.88,p=0.016),原文未提出具体影像监测方案。

核心结论

  • 颅内HPC-SFT患者需要定期、长期监测颅外转移,转移可发生于任何年龄组且可早可晚。
  • 颅外转移部位多样,通常在出现症状后确诊,原文未提出推荐的影像监测方式。
  • 更高级别的原发肿瘤转移风险更高,定期临床复查至关重要,出现复发/转移症状时应早期影像检查,影像方式取决于临床关注点。
  • 该异质性患者群体缺乏影像监测方案的高质量证据,原文认为开展适当监测的多中心研究可能有益。

研究设计与样本

  • 该系统综述按PRISMA指南检索Pubmed,检索词包括hemangiopericytoma、HPC、solitary fibrous tumor/tumour、SFT、HPC-SFT、extra-cranial metastases、metastases、recurrence、monitoring、follow-up,检索截至2018年2月1日。
  • 共纳入71项研究,并查阅所纳入文献的参考文献列表以发现其他相关文献。
  • 数据采用标准数据收集表提取,结果按研究/患者一般特征、颅外转移部位、转移检测与随访方法、原发肿瘤特征四类组织。

主要发现

  • 记录的随访时间均数范围为4至312个月,诊断时平均年龄为42.0岁。
  • 颅外转移总体发生率为28%(n=251/904),最短出现时间为3个月,最长出现时间为372个月。
  • 在71项研究中,明确颅外转移部位者共213例患者、347处转移,最常见部位为骨(未注明具体部位)(19.6%),其次为肺与胸膜(18.4%)、肝(17.6%)、椎骨(14.1%)。
  • 颅外转移性疾病通常在出现症状后确诊,关于颅外HPC-SFT监测方法的文献记录很少,未观察到明确的监测模式。
  • 更高的原发肿瘤级别(WHO III级)与颅外转移风险升高相关(1.88,p=0.016);原发肿瘤部位与治疗、局部复发、患者年龄和性别与颅外转移风险无关。

关键数值与推荐

  • 颅外转移总体发生率为28%(n=251/904)。
  • 最常见的转移部位为骨(未注明具体部位)(19.6%)、肺与胸膜(18.4%)、肝(17.6%)、椎骨(14.1%)。
  • WHO III级原发肿瘤与颅外转移风险升高相关(1.88,p=0.016)。
  • 最短至颅外转移时间为3个月,最长为372个月;记录的随访时间均数范围为4至312个月。
  • 原文未提出推荐的影像监测方式。

临床怎么用

  • 作者认为颅内HPC-SFT患者需要定期、长期监测颅外转移。
  • 作者认为定期临床复查至关重要,出现复发/转移症状时应早期影像检查,影像方式取决于临床关注点。
  • 原文未提出具体的影像监测方案,并指出该领域缺乏高质量证据。
  • 作者认为开展适当监测的多中心研究可能有益。

局限性

  • 原文指出该异质性患者群体缺乏影像监测方案的高质量证据。
  • 关于颅外HPC-SFT监测方法的文献记录很少,未观察到明确的监测模式。
  • 原文认为开展适当监测的多中心研究可能有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracranial hemangiopericytomas (HPC) and solitary fibrous tumors (SFTs) (HPC-SFT) are rare vascular tumors that resemble meningioma on imaging and predominantly affect young adults. HPC-SFT have a high rate of local recurrence with well-known propensity for extracranial metastases. This provides clinical dilemmas frequently encountered in oncology: (i) How should these patients be monitored long term? (ii) Which primary tumors are more likely to metastasize? OBJECTIVES: This systematic review aims to identify the incidence, common locations and time to presentation of extra-cranial metastases of HPC-SFT. We will assess the effect of primary tumor location, treatment, grade, patient age, gender and effect of local recurrence on rates of extra-cranial metastasis and discuss the ideal techniques by which patients with intracranial HPC-SFT should be monitored for extra-cranial metastases. METHODS: Using PRISMA guidelines the authors searched Pubmed. Search terms included hemangiopericytoma, HPC, solitary fibrous tumor/ tumour, SFT, HPC-SFT, extra-cranial metastases, metastases, recurrence, monitoring, follow-up. Studies were identified up to 1st February 2018. Reference lists of identified articles were reviewed to detect other relevant citations. Data were extracted using a standard data collection form and results organized into (i) general study/patient characteristics, (ii) location of extra-cranial metastases, (iii) methods by which metastases were detected and followed up and (iv) characteristics of primary tumors. RESULTS: Seventy-one studies were identified. Mean recorded follow up ranged from 4 to 312 months. Mean age at diagnosis was 42.0 years. The overall rate of extra-cranial metastasis was 28% (n = 251/904). The minimum time to extracranial metastases was 3 months and the maximum time was 372 months. In the 71 studies identified, where site of extra-cranial metastasis was specified, there were 347 metastases in 213 patients. The most common sites for metastases were bone (location not specified) (19.6%) followed by lung and pleura (18.4%), liver (17.6%), and vertebrae (14.1%). Extra-cranial metastatic disease is typically diagnosed following symptomatic presentation. There is little documentation of methods used to monitor patients with extra-cranial HPC-SFT and no clear surveillance paradigm observed. Higher primary tumor grade (WHO Grade III) was associated with a 1.88 (p = 0.016) increased risk of extra-cranial metastasis. Location and treatment of primary tumor, local recurrence, patient age and gender were not. CONCLUSION: Patients with intracranial HPC-SFT require periodic, long term monitoring for extra-cranial metastases. Metastases occur in any age group and can occur early and late. They vary in location and are typically diagnosed following symptomatic presentation. There is no suggested imaging modality for surveillance. Higher grade primary tumors have a greater risk of metastasis. Regular clinical review is essential with early imaging for symptoms of recurrence/metastasis with imaging modality dependent on clinical concern. Quality evidence for an imaging surveillance protocol in this heterogeneous group of patients is lacking. A multicenter study on appropriate surveillance may be of benefit.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ratneswaren T, Hogg FRA, Gallagher MJ, et al. Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease. J Neurooncol. 2018. PMID: 29551003. doi:10.1007/s11060-018-2836-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。